A patient with LUAC, harboring novel NTRK fusion (NCOR2-NTRK1), was treated with camrelizumab (anti-PD-1 mAb) and PD was observed, despite high TMB and PD-L1 positivity (20–30% of tumor cells). Here, CD274 is linked to neoplasm.